Publicacións nas que colabora con EVA MARÍA CIRUELOS GIL (13)

2024

  1. Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort

    Breast Cancer Research and Treatment, Vol. 206, Núm. 3, pp. 551-559

  2. Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey

    Clinical and Translational Oncology, Vol. 26, Núm. 8, pp. 2060-2069

2023

  1. CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 8, pp. 1557-1568

2022

  1. Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (Breast Cancer Research and Treatment, (2021), 189, 3, (689-699), 10.1007/s10549-021-06334-0)

    Breast Cancer Research and Treatment

  2. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24

  3. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2021

  1. Expected medium- And long-term impact of the COVID-19 outbreak in oncology

    JCO Global Oncology, Vol. 7, pp. 162-172

  2. Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

    Breast Cancer Research and Treatment, Vol. 189, Núm. 3, pp. 689-699

  3. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  4. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

2020

  1. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer

    Future Oncology, Vol. 16, Núm. 33, pp. 2763-2778

  2. Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

    Clinical and Translational Oncology, Vol. 22, Núm. 10, pp. 1857-1866

2018

  1. Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii91-viii92